Search
Lovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigational[A174580,A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as lovastatin are thought to enter endothelial cells by passive diffusion … [A174550] Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaZucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin has also been evaluated for the management of several conditions manifested by chronic nerve pain. … Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain.
Categories: Topical Products for Joint and Muscular PainSpecific infections by free-living amoebae
go.drugbank.com/conditions/DBCOND0089199Drugs: MiltefosineSynonyms: Disease due to Endamoebidae (disorder)Hemorrhagic disease of the newborn
go.drugbank.com/conditions/DBCOND0022633Drugs: PhylloquinoneSynonyms: Hemorrhagic disease of the newborn due to vitamin K deficiency (disorder)Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalHowever, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008. … Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113] … [A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi.
Categories: Compounds used in a research, industrial, or household settingUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7719] However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive … Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD).
Categories: Agents to Treat Airway Disease, Drugs for Obstructive Airway DiseasesMigalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigational[L47036,L47057] Galafold also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. … serious conditions where there is an unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients.
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Synonyms: DB-OTO